1768

79. WHO (2014). Weekly epidemiological record. No. 21, 2014, 89, 221‒236.

1804

91. Iversen, O. E., et al. (2016). Immunogenicity of the 9-Valent HPV Vaccine Using 2-

1769

80.

Romanowski, B., et al. (2016). Sustained immunogenicity of the HPV-16/18 AS04-

1805

Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. Jama 316(22): 2411-2421.

1770

adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical

1806

92.

1771

data and modeling predictions from a randomized study. Hum Vaccin Immunother 12(1): 20-

1807

nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim

Olsson, S. E., et al. (2020). Long-term immunogenicity, effectiveness, and safety of

1772

29.

1808

analysis after 8 years of follow-up. Papillomavirus Res 10: 100203.

1773

81. Romanowski, B., et al. (2011). Immunogenicity and safety of the HPV-16/18 AS04-

1809

93.

1774

adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose

1810

Infection and disease in males. N Engl J Med 364(5): 401-411.

1775

schedule: results from a randomized study. Hum Vaccin 7(12): 1374-1386.

1811

94. Garland, S. M., et al. (2018). Efficacy, Immunogenicity, and Safety of a 9-Valent Human

1776

82. Dobson, S. R., et al. (2013). Immunogenicity of 2 doses of HPV vaccine in younger

1812

Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. J Infect Dis

1777

adolescents vs 3 doses in young women: a randomized clinical trial. Jama 309(17): 1793-1802.

1813

218(1): 95-108.

1778

83. D'Addario, M., et al. (2017). Two-dose schedules for human papillomavirus vaccine:

1814

95. Iwata, S., et al. (2017). Safety and Immunogenicity of a 9-Valent Human Papillomavirus

1779

Systematic review and meta-analysis. Vaccine 35(22): 2892-2901.

1815

Vaccine Administered to 9- to 15-Year-Old Japanese Girls. Jpn J Infect Dis 70(4): 368-373.

1780

84.

Leung, T. F., et al. (2015). Comparative immunogenicity and safety of human

1816

96.

Giuliano, A. R., et al. (2011). Efficacy of quadrivalent HPV vaccine against HPV

Kudo, R., et al. (2019). Bivalent Human Papillomavirus Vaccine Effectiveness in a

1781

papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine

1817

Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-

1782

administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month

1818

Protection. J Infect Dis 219(3): 382-390.

1783

12 from a randomized trial. Hum Vaccin Immunother 11(7): 1689-1702.

1819

97. Tanaka, H., et al. (2017). Preventive effect of human papillomavirus vaccination on the

1784

85.

Bergman, H., et al. (2019). Comparison of different human papillomavirus (HPV)

1820

development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res

1785

vaccine types and dose schedules for prevention of HPV-related disease in females and males.

1821

43(10): 1597-1601.

1786

Cochrane Database Syst Rev 2019(11).

1822

98. Ozawa, N., et al. (2017). Lower Incidence of Cervical Intraepithelial Neoplasia among

1787

86.

Leung, T. F., et al. (2018). Comparative immunogenicity and safety of human

1823

Young Women with Human Papillomavirus Vaccination in Miyagi, Japan. Tohoku J Exp Med

1788

papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered

1824

243(4): 329-334.

1789

according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from

1825

99. Konno, R., et al. (2018). Effectiveness of HPV vaccination against high grade cervical

1790

a randomized trial. Vaccine 36(1): 98-106.

1826

lesions in Japan. Vaccine 36(52): 7913-7915.

1791

87. Donken, R., et al. (2020). Immunogenicity of 2 and 3 Doses of the Quadrivalent Human

1827

100. Shiko, Y., et al. (2020). Effectiveness of HPV vaccination against the development of

1792

Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized

1828

high-grade cervical lesions in young Japanese women. BMC Infect Dis 20(1): 808.

1793

Clinical Trial. Clin Infect Dis 71(4): 1022-1029.

1829

101. Karube, A., et al. (2019). Reduction in HPV 16/18 prevalence among young women

1794

88.

Dehlendorff, C., et al. (2018). Effectiveness of varying number of doses and timing

1830

following HPV vaccine introduction in a highly vaccinated district, Japan, 2008-2017. J Rural

1795

between doses of quadrivalent HPV vaccine against severe cervical lesions. Vaccine 36(43):

1831

Med 14(1): 48-57.

1796

6373-6378.

1832

102. Yagi, A., et al. (2019). Evaluation of future cervical cancer risk in Japan, based on birth

1797

89. Huh, W. K., et al. (2017). Final efficacy, immunogenicity, and safety analyses of a nine-

1833

year. Vaccine 37(22): 2889-2891.

1798

valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind

1834

103. Ueda, Y., et al. (2018). Dynamic changes in Japan's prevalence of abnormal findings in

1799

trial. Lancet 390(10108): 2143-2159.

1835

cervical cervical cytology depending on birth year. Sci Rep 8(1): 5612.

1800

90.

Vesikari, T., et al. (2015). A Randomized, Double-Blind, Phase III Study of the

1836

104.

1801

Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle

1837

women with high-grade cervical lesions following the Japanese HPV vaccination program.

1802

Vaccine (V503) Versus Gardasil(R) in 9-15-Year-Old Girls. Pediatr Infect Dis J 34(9): 992-

1838

Cancer Sci 110(12): 3811-3820.

1803

998.

1839

105.

87

Matsumoto, K., et al. (2019). Reduction in HPV16/18 prevalence among young

Ikeda S, Ueda Y, et al. (2020). Human papillomavirus vaccine to prevent cervical

88